Skip to main content
Toggle Menu of ADA WebSites
ADA Websites
Partnerships and Commissions
Toggle Search Area
Toggle Menu
e-mail Print Share

FDA extends approval of HPV vaccine for people 27-45

October 10, 2018 People 27 to 45 are now approved to get the human papillomavirus vaccine, the U.S. Food and Drug Administration announced Oct. 5.

The vaccine, Gardasil 9, prevents certain cancers and disease caused by the nine HPV types covered by the vaccine. The vaccine was previously approved for those aged 9 to 26 years.

Each year about 14 million Americans become infected with HPV, according to the Centers for Disease Control and Prevention. HPV is a major risk factor for several cancers in men and women, including cervical, vulvar, vaginal, penile, anal and oropharyngeal cancers.

Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research said in a news release that the recent announcement "represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range."

For more information from the FDA on this topic, visit FDA.gov. For more information from the ADA about oral cancers and HPV, visit ADA.org.

Dentists can also refer patients to the ADA's consumer website, MouthHealthy.org, for general information about oral head and neck cancer and HPV.

An ADA continuing education course about HPV-related orophayrngeal cancer is available online. To access the course, visit ADA.org and search for "HPV Infection, Risk Factors, and HPV-Related Oropharyngeal Cancer."